ALS Treatments, Neuroplasticity & Biotech | Longevity News Roundup — Week 3, 2026

Sponsor: The Longevity ShowWebsite: https://longevityshow.com/The Longevity Show is a science and wellness festival in London focused on healthy aging, cutting‑edge longevity research, practical health‑span strategies, expert talks, and an interactive expo.__________________In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick unpack the biggest stories shaping the longevity ecosystem, from breakthrough neurological therapeutics and pet longevity innovations to advances in neuroplasticity, wearable tech, and early-stage cardiovascular interventions.Vector Y’s ALS drug, VTX002, received Fast Track designation, targeting the TDP43 protein and marking a potential shift from symptom management to disease modification in ALS.Loyal’s senior dog longevity drug, LOY002, clears FDA safety hurdles, aiming to extend lifespan in large mammals while providing insights for human longevity applications.Cumulus introduces a scalable neuroplasticity measurement platform with wireless dry EEG sensors, allowing researchers to monitor brain adaptation and recovery in clinical settings efficiently.Significant investment activity continues in longevity-focused startups, including multi-million-dollar raises for cardiovascular disease prevention, extracellular matrix-targeted therapies, and regenerative biologics.__________________News & References:Vector Y wins FDA Fast Track for ALS therapy → https://longevity.technology/news/vectory-wins-fda-fast-track-for-als-therapy/FDA clears safety step for Loyal’s senior dog longevity drug → https://longevity.technology/news/fda-clears-safety-step-for-loyals-senior-dog-longevity-drug/Cumulus proves brain plasticity can be measured at scale → https://longevity.technology/news/cumulus-proves-brain-plasticity-can-be-measured-at-scale/Nvidia and Eli Lilly bet $1 billion on AI-powered drug discovery → https://longevity.technology/news/nvidia-and-eli-lilly-bet-1-billion-on-ai-powered-drug-discovery/50M boost secured for BioBeat’s wearable blood pressure tech → https://longevity.technology/news/50m-boost-secured-for-biobeats-wearable-blood-pressure-tech/Engitix raises $25M to target tissue aging at its source → https://longevity.technology/news/engitix-raises-25m-to-target-tissue-aging-at-its-source/Corsera lands $80M to predict and prevent cardiovascular disease → https://longevity.technology/news/corsera-lands-80m-to-predict-and-prevent-cardiovascular-disease/Proxima lands $80M to make protein interactions programmable → https://longevity.technology/news/proxima-lands-80m-to-make-protein-interactions-programmable/__________________Hosts:Phil Newman: https://qrco.de/bgXpNYNina Patrick: https://qrco.de/bgXpKn